OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
11
Results
Show all
Save search
Copy query
Show results for
Unknown
(11)
Publication Date
Release Date
2018
(5)
2017
(3)
2023
(1)
2020
(1)
2019
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
Not available
S-EPMC5485164
|
biostudies-literature
Cite
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
Not available
S-EPMC6033097
|
biostudies-literature
Cite
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
Not available
S-EPMC6175384
|
biostudies-literature
Cite
Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.
Not available
S-EPMC6585811
|
biostudies-literature
Cite
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies.
Not available
S-EPMC5984942
|
biostudies-literature
Cite
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.
Not available
S-EPMC6763278
|
biostudies-literature
Cite
Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab.
Not available
S-EPMC7549294
|
biostudies-literature
Cite
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
Not available
S-EPMC5969299
|
biostudies-literature
Cite
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
Not available
S-EPMC5698740
|
biostudies-literature
Cite
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
Not available
S-EPMC5445362
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets